Quick answers
- What is Mirvetuximab soravtansine used for?
- The FDA-approved label (Elahere, ImmunoGen, Inc., July 14, 2025) says: “ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Mirvetuximab soravtansine?
- The “Adverse Reactions” section of the FDA label (Elahere, ImmunoGen, Inc., July 14, 2025) begins: “The following adverse reactions are discussed elsewhere in the labeling: Ocular Disorders [see Warnings and Precautions (5.1)]. Pneumonitis [see Warnings and Precautions (5.2)]. Peripheral Neuropathy [see Warnings and Precautions (5.3)].” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Mirvetuximab soravtansine?
- The “Drug Interactions” section of the FDA label (Elahere, ImmunoGen, Inc., July 14, 2025) begins: “Strong CYP3A4 Inhibitors: Closely monitor for ELAHERE adverse reactions. (7.1) 7.1 Effects of Other Drugs on ELAHERE Strong CYP3A4 Inhibitors DM4 is a CYP3A4 substrate. Concomitant use of ELAHERE with strong CYP3A4 inhibitors may increase unconjugated DM4 exposure [see Clinical Pharmacology (12.3)], which may increase the risk of ELAHERE adverse reactions [see Adverse Reactions (6)].” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Mirvetuximab soravtansine have a boxed warning?
- Yes. The FDA label for Elahere has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Mirvetuximab soravtansine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Mirvetuximab soravtansine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Mirvetuximab soravtansine?
- 1 company lists prescription products of Mirvetuximab soravtansine in the FDA NDC Directory, including ImmunoGen, Inc.
What Mirvetuximab soravtansine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test […]. …
— FDA label: Elahere, ImmunoGen, Inc., effective July 14, 2025. Read the full label on DailyMed →
Label quoted: the one for the most common form (injection, solution, intravenous), Elahere, ImmunoGen, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
Mirvetuximab soravtansine boxed warning: what the label says
Quoted from the boxed warning of the FDA-approved label.
WARNING: OCULAR TOXICITY ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated [see Dosage and Administration (2.3)].
Read more of this section
Administer prophylactic artificial tears and ophthalmic topical steroids [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose [see Dosage and Administration (2.4) and Warnings and Precautions (5.1)]. Discontinue ELAHERE for Grade 4 ocular toxicities [see Dosage and Administration (2.4) and Warnings and Precautions (5.1)]. WARNING: OCULAR TOXICITY See full prescribing information for complete boxed warning. ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. (5.1, 6.1) Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated. (2.3) Administer prophylactic artificial tears and ophthalmic topical steroids. (2.3, 5.1) Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose. (2.4, 5.1) Discontinue ELAHERE for Grade 4 ocular toxicities. (2.4, 5.1)
— FDA label: Elahere, ImmunoGen, Inc., effective July 14, 2025. Read the full label on DailyMed →
Mirvetuximab soravtansine side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following adverse reactions are discussed elsewhere in the labeling: Ocular Disorders [see Warnings and Precautions (5.1)]. Pneumonitis [see Warnings and Precautions (5.2)]. Peripheral Neuropathy [see Warnings and Precautions (5.3)].
Read more of this section
The most common (≥20 %) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in Warnings and Precautions reflect exposure to ELAHERE in 682 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer at 6 mg/kg AIBW administered intravenously once every 3 weeks until disease progression or unacceptable toxicity in Study 0416, Study 0417, Study 0403 (NCT02631876), and Study 0401 (NCT01609556). The median duration of treatment was 4.4 months (range: 1.0 to 30.0). In the pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils. Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Study 0416 The safety of ELAHERE was evaluated in Study 0416, a multicenter, open-label, active-controlled, randomized, two-arm, study in patients (n=453) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer [see Clinical Studies (14)]. Patients received ELAHERE 6 mg/kg AIBW once every 3 weeks until disease progression or unacceptable toxicity. The median duration of treatment was 5 months (range: 0.69 to 27.4). Serious adverse reactions occurred in 24% of patients treated with ELAHERE. The most common (≥2%) serious adverse reactions were intestinal obstruction (5%), abdominal pain (3%), and pleural effusion (3%).
— FDA label: Elahere, ImmunoGen, Inc., effective July 14, 2025. This is part of the section. Read the full label on DailyMed →
Mirvetuximab soravtansine drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Strong CYP3A4 Inhibitors: Closely monitor for ELAHERE adverse reactions. (7.1) 7.1 Effects of Other Drugs on ELAHERE Strong CYP3A4 Inhibitors DM4 is a CYP3A4 substrate. Concomitant use of ELAHERE with strong CYP3A4 inhibitors may increase unconjugated DM4 exposure [see Clinical Pharmacology (12.3)], which may increase the risk of ELAHERE adverse reactions [see Adverse Reactions (6)].
Read more of this section
Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors [see Warnings and Precautions (5)].
— FDA label: Elahere, ImmunoGen, Inc., effective July 14, 2025. Read the full label on DailyMed →
Mirvetuximab soravtansine dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Administer ELAHERE as an intravenous infusion only after dilution in 5% Dextrose Injection, USP. ELAHERE is incompatible with normal saline. (2.5) The recommended dose of ELAHERE is 6 mg/kg adjusted ideal body weight administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. (2.2) Premedicate with a corticosteroid, antihistamine, and antipyretic.
Read more of this section
(2.3) Premedicate with an antiemetic, ophthalmic topical steroids, and lubricating eye drops. (2.3, 5.1) See full Prescribing Information for preparation and administration instructions and dose modifications for adverse reactions. (2) 2.1 Patient Selection Select patients for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer with ELAHERE based on the presence of FRα tumor expression [see Indications & Usage (1) and Clinical Studies (14)] using an FDA-approved test. Information on FDA-approved tests for the measurement of FRα tumor expression is available at http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosage of ELAHERE is 6 mg/kg adjusted ideal body weight (AIBW) administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease progression or unacceptable toxicity [see Dosage and Administration (2.5)]. Dosing based on AIBW reduces exposure variability for patients who are either under or overweight. The total dose of ELAHERE is calculated based on each patient’s AIBW using the following formula: AIBW = Ideal Body Weight (IBW [kg]) + 0.4*(Actual weight [kg] – IBW) Female IBW [kg] = 0.9*height[cm] – 92 2.3 Premedication and Required Eye Care Premedica tion Administer the premedications in Table 1 prior to each infusion of ELAHERE to reduce the incidence and severity of infusion related reactions (IRRs), nausea, and vomiting. Table 1: Premedication Prior to Each ELAHERE Infusion Premedication Route of Administration Examples (or equivalent) Administration Time Prior to ELAHERE Infusion Corticosteroid intravenous dexamethasone 10 mg Antihistamine oral or intravenous diphenhydramine 25 mg to 50 mg At least 30 minutes prior Antipyretic oral or intravenous acetaminophen 325 mg to 650 mg Antiemetic oral or intravenous 5-HT 3 serotonin receptor antagonist or appropriate alternatives Before each dose and thereafter as needed Consider additional premedications including corticosteroids the day prior to ELAHERE administration for patients who experienced IRRs. Ophthalmic Exams and Premedication Ophthalmic E xam: Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated. Ophthalmic Topical Steroids: The use of ophthalmic topical steroids is recommended. The initial prescription and renewals of any corticosteroid medication should be made only after examination with a slit lamp. Administer one drop of ophthalmic topical steroids in each eye 6 times daily starting the day prior to each infusion until day 4; then administer one drop in each eye 4 times daily for days 5-8 of each cycle of ELAHERE [see Warnings and Precautions (5.1)].
Table from the label
| Premedication | Route of Administration | Examples (or equivalent) | Administration Time Prior to ELAHERE Infusion |
|---|---|---|---|
| Corticosteroid | intravenous | dexamethasone 10 mg | |
| Antihistamine | oral or intravenous | diphenhydramine 25 mg to 50 mg | At least 30 minutes prior |
| Antipyretic | oral or intravenous | acetaminophen 325 mg to 650 mg | |
| Antiemetic | oral or intravenous | 5-HT3 serotonin receptor antagonist or appropriate alternatives | Before each dose and thereafter as needed |
— FDA label: Elahere, ImmunoGen, Inc., effective July 14, 2025. This is part of the section. Read the full label on DailyMed →
Mirvetuximab soravtansine in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Human immunoglobulin G (IgG) is known to cross the placental barrier; therefore, ELAHERE has the potential to be transmitted from the mother to the developing fetus.
Read more of this section
There are no available human data on ELAHERE use in pregnant women to inform a drug-associated risk. No reproductive or developmental animal toxicity studies were conducted with mirvetuximab soravtansine-gynx. Advise patients of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data: No reproductive or developmental animal toxicity studies have been conducted with mirvetuximab soravtansine-gynx. The cytotoxic component of ELAHERE, DM4, disrupts microtubule function, is genotoxic, and can be toxic to actively dividing cells, suggesting it has the potential to cause embryotoxicity and teratogenicity.
— FDA label: Elahere, ImmunoGen, Inc., effective July 14, 2025. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Elahere |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- ImmunoGen, Inc.1 product
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA761310 ELAHERE | Immunogen Inc | November 14, 2022 | 2, latest July 14, 2025 2025: Labeling · 2024: Efficacy |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2621553, 2621559 |
|---|---|
| SPL set ID of the quoted label | 00c424b5-6ccd-48ab-9e88-1986451120e2 |
| FDA labels (SPL) | 1 |
| FDA applications | BLA761310 |
| Active ingredients (FDA) | MIRVETUXIMAB SORAVTANSINE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- ImmunoGen, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Elahere, ImmunoGen, Inc., effective July 14, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →